The Fort Worth Press - First person vaccinated during trial of new Ebola jab

USD -
AED 3.672993
AFN 63.502337
ALL 80.613613
AMD 362.984224
ANG 1.790365
AOA 918.000306
ARS 1519.863298
AUD 1.426305
AWG 1.80075
AZN 1.696448
BAM 1.719362
BBD 2.013934
BDT 123.259913
BGN 1.683441
BHD 0.376975
BIF 3012.118628
BMD 1
BND 1.279555
BOB 12.083357
BRL 5.191801
BSD 0.99989
BTN 95.896685
BWP 13.671269
BYN 3.043562
BYR 19600
BZD 2.011077
CAD 1.414825
CDF 2310.000082
CHF 0.828795
CLF 0.02439
CLP 963.040182
CNY 6.71135
CNH 6.718765
COP 3358.43
CRC 454.603398
CUC 1
CUP 23.997046
CVE 96.934985
CZK 21.45945
DJF 178.062622
DKK 6.57376
DOP 59.421086
DZD 133.648751
EGP 51.778596
ERN 15
ETB 163.328249
EUR 0.87937
FJD 2.24725
FKP 0.754629
GBP 0.756805
GEL 2.614982
GGP 0.754629
GHS 11.588419
GIP 0.754629
GMD 73.502618
GNF 8793.962118
GTQ 7.636078
GYD 209.201637
HKD 7.843555
HNL 26.835755
HRK 6.6254
HTG 130.857718
HUF 321.952502
IDR 17950
ILS 3.04725
IMP 0.754629
INR 95.94225
IQD 1309.861322
IRR 1374574.999833
ISK 120.649786
JEP 0.754629
JMD 157.698783
JOD 0.708981
JPY 158.407497
KES 129.540408
KGS 87.449699
KHR 4067.745948
KMF 432.999976
KPW 900.000318
KRW 1360.226387
KWD 0.30885
KYD 0.83322
KZT 441.682088
LAK 22412.209177
LBP 89544.067871
LKR 330.008835
LRD 171.983174
LSL 16.425661
LTL 2.95274
LVL 0.60489
LYD 6.394922
MAD 9.573588
MDL 17.793016
MGA 4383.315971
MKD 54.087199
MMK 2099.566963
MNT 3597.939506
MOP 8.077009
MRU 40.026198
MUR 47.450485
MVR 15.450202
MWK 1733.809819
MXN 17.74077
MYR 4.076102
MZN 63.910134
NAD 16.425805
NGN 1326.319561
NIO 36.800485
NOK 9.52804
NPR 153.437218
NZD 1.769115
OMR 0.384491
PAB 0.999899
PEN 3.387384
PGK 4.454545
PHP 62.645499
PKR 277.045789
PLN 3.85265
PYG 5925.404954
QAR 3.644699
RON 4.640103
RSD 103.241005
RUB 85.000374
RWF 1479.316211
SAR 3.762907
SBD 8.000512
SCR 13.926164
SDG 601.504684
SEK 9.928435
SGD 1.279215
SHP 0.755002
SLE 24.649996
SLL 20969.491881
SOS 571.436107
SRD 37.695037
STD 20697.981008
STN 21.538651
SVC 8.748896
SYP 13002.000254
SZL 16.42205
THB 33.435503
TJS 9.214019
TMT 3.51
TND 2.957763
TOP 2.40776
TRY 48.9475
TTD 6.800789
TWD 31.774198
TZS 2644.998012
UAH 45.01655
UGX 3924.343855
UYU 40.061362
UZS 11808.195936
VES 852.43145
VND 25986
VUV 118.51472
WST 2.751818
XAF 576.828598
XAG 0.015637
XAU 0.000233419076
XCD 2.70255
XCG 1.801982
XDR 0.707052
XOF 576.828598
XPF 104.842574
YER 236.64984
ZAR 16.42023
ZMK 9001.194046
ZMW 19.448767
ZWL 321.999592
SSP 5712.591861
MXV 2.010544
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

First person vaccinated during trial of new Ebola jab
First person vaccinated during trial of new Ebola jab / Photo: © AFP/File

First person vaccinated during trial of new Ebola jab

A volunteer was injected on Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.

Text size:

More than 1,000 people have been killed in the DRC and Uganda since the outbreak emerged in May, according to the World Health Organization.

Researchers and health organisations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage where it is tested on humans.

Earlier this month, a team at Oxford University in the UK announced it was launching the first trial for its ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca's Covid-19 vaccine.

The first dose was administered to a 37-year-old volunteer named Ed Hunt in Oxford on Friday, a university spokesman told AFP.

"We've taken this vaccine candidate from concept to clinic in just eight weeks," David Pulido-Gomez of Oxford's Pandemic Sciences Institute said in a statement.

"Reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort," he added.

The trial received funding from the Coalition for Epidemic Preparedness Innovations (CEPI), while the Serum Institute of India has already manufactured a stockpile of 620,000 doses.

The phase 1 trial plans to assess the safety and effectiveness of the vaccine in 50 health adults in the coming weeks. The researchers are currently recruiting more volunteers.

Given regulatory approval, the team is preparing for more clinical studies of the vaccine with partners in Uganda, Oxford said.

Several other Bundibugyo vaccine candidates are also being urgently developed towards the trial stage, while two potential treatments are being worked on.

The Ebola outbreak is the 17th in the DRC's history, but just the third caused by the Bundibugyo strain, for which there are no approved vaccines or treatments.

WHO chief Tedros Adhanom Ghebreyesus warned last week that the outbreak had over the past month "expanded faster than any previous outbreak" of Ebola.

The outbreak has remained concentrated in the vast country's mineral-rich and conflict-plagued northeastern province.

Cases of Ebola, which spreads through close contact and infected bodily fluids, have also been found in four other DRC provinces.

T.M.Dan--TFWP